Manufacturing a Stronger Standard: Robotic Finishing – More than a Program Path

Lesta and Wagner have over a decade of proven experience in automation together for general industry in Europe. DeGeest brought Lesta’s automation technology to the U.S. to build their robotic finishing system for metal their fabrication customers and opened LestaUSA to bring those solutions to the rest of North American companies. Wagner’s North American Systems group recognized the potential right away by becoming the first LestaUSA Equipment Partner and provided equipment for LestaUSA’s Integration Center and Test Lab. With each successful installation, that partnership has continued to grow, and now LestaUSA has integrated one of their self-learning robots into Wagner’s test lab as well. JR Rogers, National Sales Manager, Engineered Systems, at Wagner, joined Derek DeGeest to discuss this exciting collaboration of technology and expertise.

With this distribution partnership, Rogers said it allows Wagner to offer a fully automated application packaged for its customers on complex parts. “Automation means a lot of different things,” Rogers said. “But when someone says I can’t find labor; I can’t keep labor, I need to go automated, that means 100% automation and no manual intervention from the coating application. With the partnership with LestaUSA, we have a viable solution to provide customers with something they can bring to their system.”

This combination of Wagner equipment for paint applications and Lesta’s self-learning finishing robots create a powerful tool that learns from the manufacturing experts who do the painting. The self-learning robots enter into a weightless learning mode and allows painters to paint a part in real time with Lesta’s robot. The robot records every movement, gun angle, trigger pull and gun preset creating an automated robotic program in minutes. The painter becomes the programming expert, and the robot is the tool doing the labor. This allows the painter to step out of the booth to work on improving quality and production potential of the system.

LestaUSA and Wagner will debut their partnership at IWF (The International Woodworking Fair®) 2022 in Atlanta. “I’m looking forward to having people come in and see in our booth the Lesta robot in combination with our product and seeing the different ways it can be used,” Rogers said. “And we can supply a fully automated system, not just the gun and the plural component of the pump, but we can actually supply the robot in partnership with DeGeest and Lesta Self-Learning Finishing Robotics.”

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More